ALSO NOTED: Novartis taps Immusol; OncoGenex attracts venture funds; Venture fund wins settlement money; and much more...

> Novartis taps Immusol for three-year, $78 million R&D partnership using the latter's gene inactivation technology. Release

> OncoGenex attracts more than $12 million in venture money to finance development of targeted cancer treatments. Release

> Commerce Health Ventures, a Pennsylvania venture fund, won $9.1 million in tobacco-settlement money to invest in life sciences start-ups. Story

> Savient Pharmaceuticals delayed its second-quarter report because it needs more time to evaluate possible errors in previous financial statements. Report

> Chiron inked a deal with Dutch biotech Crucell and allied contract manufacturer DSM Biologics for a recombinant protein to be used in Chiron's hepatitis C vaccine, currently in phase I clinical trials. Release

> IsoTis OrthoBiologics won FDA approval for use of its DynaGraft II synthetic bone-graft material in teeth; the compound got clearance for orthopaedic use earlier this year. Release

> Hawaii Biotech's West Nile vaccine shows 100 percent protection in a third animal study. Release

> North Carolina-based Regado Biosciences, a spin-off from Duke University Medical Center's surgery department that is developing an anticoagulant drug, has raised $20 million in second-round venture capital funding. Report

> WEX Pharmaceuticals is seeking a replacement for its CEO, recently sent to Asia to head up operations there. Release

And Finally... Biologists are struggling to construct a working electronic model of E. coli -- from scratch. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.